Pharmaceutical Executive May 28, 2024
The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion.
Johnson & Johnson (J&J) announced that it has agreed to terms with Numab Therapeutics to acquire its wholly owned subsidiary for the global rights to NM26, an investigational bispecific antibody currently in Phase II of development for the treatment of atopic dermatitis (AD). Under terms of the deal, J&J will pay Numab around $1.25 billion in an all-cash transaction. According to the company, the transaction is expected to close later this year, clearance under the Hart-Scott-Rodino Antitrust Improvements Act and fulfillment of customary closing conditions.
NM26 targets two established pathways, interleukin (IL)-4Rα and IL-31, in AD. According to investigators, this works by targeting...
Today's Sponsors
Today's Sponsor